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Editorial Decision 10 June 2020.
Abstract
Recent anecdotal and scientific reports have provided evidence of a link between COVID-19 and 
chemosensory impairments, such as anosmia. However, these reports have downplayed or failed 
to distinguish potential effects on taste, ignored chemesthesis, and generally lacked quantita-
tive measurements. Here, we report the development, implementation, and initial results of a 
multilingual, international questionnaire to assess self-reported quantity and quality of percep-
tion in 3 distinct chemosensory modalities (smell, taste, and chemesthesis) before and during 
COVID-19. In the first 11 days after questionnaire launch, 4039 participants (2913 women, 1118 men, 
and 8 others, aged 19–79) reported a COVID-19 diagnosis either via laboratory tests or clinical as-
sessment. Importantly, smell, taste, and chemesthetic function were each significantly reduced 
compared to their status before the disease. Difference scores (maximum possible change ±100) 
revealed a mean reduction of smell (−79.7 ± 28.7, mean ± standard deviation), taste (−69.0 ± 32.6), 
and chemesthetic (−37.3 ± 36.2) function during COVID-19. Qualitative changes in olfactory ability 
(parosmia and phantosmia) were relatively rare and correlated with smell loss. Importantly, per-
ceived nasal obstruction did not account for smell loss. Furthermore, chemosensory impairments 
were similar between participants in the laboratory test and clinical assessment groups. These 
results show that COVID-19-associated chemosensory impairment is not limited to smell but also 
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affects taste and chemesthesis. The multimodal impact of COVID-19 and the lack of perceived nasal 
obstruction suggest that severe acute respiratory syndrome coronavirus strain 2 (SARS-CoV-2) in-
fection may disrupt sensory-neural mechanisms.
Key words:  head and neck surgery, olfaction, somatosensation Pennsylvania State University
Introduction
In late 2019, a new virus, severe acute respiratory syndrome corona-
virus strain 2 (SARS-CoV-2), was reported in Wuhan, China (Zhu 
et al. 2020). The resulting COVID-19 disease has become a global 
pandemic with 3.18 million reported cases as of May 1, 2020 (World 
Health Organization 2020). When assessing SARS-CoV-2 infection, 
clinicians initially focused on symptoms such as fever, body aches, and 
dry cough. However, emerging reports suggest sudden olfactory loss 
(anosmia or hyposmia) may be prevalent in patients with COVID-19 
(Menni et al. 2020; Vetter et al. 2020). Olfactory disorders have long 
been associated with viral upper respiratory tract infections (URI) 
that cause the common cold and flu, including influenza and para-
influenza viruses, rhinoviruses, and other endemic coronaviruses 
(Soler et al. 2020). Taste disorders have been known to occur during 
and after respiratory viral infection, as well (Hummel et al. 2011). 
One case report found anosmia presenting with SARS (Hwang 
2006). Olfactory dysfunction due to viral infections may account for 
11–45% of all olfactory disorders excluding presbyosmia (Nordin 
and Brömerson 2008). The estimated prevalence of COVID-19-
associated olfactory impairment may be higher than in COVID-19-
independent postviral olfactory loss; estimations range from 5% to 
85% in self-report studies, with differences noted between mild and 
severe cases (Bagheri et al. 2020; Gane et al. 2020; Giacomelli et al. 
2020; Haldrup et al. 2020; Hopkins et al. 2020; Lechien, Cabaraux, 
et al. 2020; Lechien, Chiesa-Estomba, et al. 2020; Mao et al. 2020; 
Menni et  al. 2020; Yan, Faraji, Prajapati, Boone et  al. 2020; Yan, 
Faraji, Prajapati, Ostrander 2020). When psychophysical odor iden-
tification tests are used, this prevalence ranges from 76% in Europe 
using the Sniffin’ Sticks (Lechien, Chiesa-Estomba, et  al. 2020) to 
98% in Iran using the University of Pennsylvania Smell Identification 
Test (UPSIT) (Moein et al. 2020), though the severity of COVID-19 
in these study cohorts may not be representative of the larger popu-
lation. These anecdotes, preprints, letters, and peer-reviewed reports 
(for a review, see Pellegrino et al. 2020) describe chemosensory dis-
turbances in COVID-19 with characteristics that are similar to those 
seen in common URIs, such as isolated sudden onset of anosmia 
(Gane et al. 2020), occurrence of anosmia in mild or asymptomatic 
cases of COVID-19 (Hopkins et al. 2020), and loss of taste (Lechien, 
Cabaraux, et al. 2020; Yan, Faraji, Prajapati, Boone et al. 2020). As 
of May 13, 2020, the European Centre for Disease Prevention and 
Control, the World Health Organization, and the following coun-
tries or regions have listed smell loss as a symptom of COVID-19: 
Argentina, Chile, Denmark, Finland, France, Italy, Luxembourg, 
New Zealand, Singapore, South Africa, Slovenia, Spain, Switzerland, 
The Netherlands, and the United States; many other countries or re-
gions have not yet officially acknowledged smell loss as a symptom 
of COVID-19. To date, quantitative studies to determine the extent 
and detail of broad chemosensory changes in COVID-19 are rare, 
with the exception of 2 recent studies: Iravani et al. (2020) assessed 
odor intensity in a group of Swedish respondents, whereas Moein 
et al. (2020) tested a small sample of hospitalized Iranian patients 
with the UPSIT. We use 3 separate sensory modalities—smell, taste 
and chemesthesis—to sense our chemical environment in daily life. 
The olfactory system (smell) detects volatile chemicals through ol-
factory sensory neurons in the nasal cavity. Odors in the external 
environment are sampled through the nostrils (orthonasal olfaction), 
whereas odors coming from food or drink in the mouth are sampled 
via the nasopharynx (retronasal olfaction). The gustatory system 
(taste) responds to nonvolatile compounds in the mouth that elicit 
sensations of sweet, salty, bitter, sour, and umami (savory). Finally, 
chemesthesis detects other chemicals, often found in herbs or spices 
that evoke sensations like burning, cooling, or tingling.
Although taste has occasionally been explored with respect to 
COVID-19 (e.g., Giacomelli et al. 2020; Yan, Faraji, Prajapati, Boone 
et al. 2020; Yan, Faraji, Prajapati, Ostrander 2020), chemesthesis re-
mains unexamined in recent studies despite anecdotal reports that 
it may be similarly compromised in persons with COVID-19. Smell, 
taste, and chemesthesis are often conflated, mostly because they 
produce a single experience of flavor during eating (Rozin 1982; 
Spence et al. 2014; Duffy and Hayes 2019; Hayes 2019), and pa-
tients often report a loss of taste when, in fact, they are experiencing 
a loss of retronasal olfaction. Nevertheless, the olfactory and gus-
tatory systems, along with parts of the somatosensory system that 
conveys chemesthesis, are separate sensory systems with distinct 
peripheral and central neural mechanisms (Shepherd 2006; Green 
2012). To date, the impact of COVID-19 on each of these 3 chemo-
sensory modalities remains poorly understood.
Chemosensory disturbances can result in quantitative reductions 
in smell or taste (i.e., anosmia/hyposmia and ageusia/hypogeusia, re-
spectively) or qualitative changes in these senses (e.g., distortions of 
smell and taste, termed parosmia and dysgeusia, or phantom sensa-
tions, termed phantosmia and phantogeusia). These key distinctions 
have been neglected in previous reports. Because these phenomena are 
not necessarily correlated and have different mechanisms (Holbrook 
et al. 2005; Reden et al. 2007; Iannilli et al. 2019), understanding 
how COVID-19 impacts chemosensation in both quantitative and 
qualitative ways should provide important insights into the mech-
anisms by which the SARS-CoV-2 virus affects the chemical senses.
Ideally, validated testing of chemosensory function would be com-
bined with a review of a patient’s medical records, including labora-
tory test results (from viral swab or serology, “Lab Test”) to confirm 
the infectious agent. Due to limited laboratory test availability in many 
countries, the necessity in some medical settings for social distancing, 
and a potentially large number of asymptomatic or mild cases, it has 
been impractical or impossible to conduct such chemosensory testing 
for many individuals with COVID-19. Additionally, in many countries 
where testing resources are limited, laboratory testing has been limited 
to the most severe cases. Another diagnosis method is a clinical assess-
ment by a medical professional (“Clinical Assessment”), either in of-
fice or remotely via telemedicine. Thus, the method of diagnosis—Lab 
Test versus Clinical Assessment—may be associated with differences in 
symptom severity, including severity of chemosensory impairments. To 
account for possible differences in the severity of infection, as well as the 
availability of diagnosis options across countries, we collected informa-
tion on diagnosis methods and compared chemosensory function be-
tween participants diagnosed with Lab Test versus Clinical Assessment.
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Given all the issues raised above, we deployed a crowd-sourced, 
multilingual, online study with a global reach (as of May 1, 2020, 
deployed in 27 languages).  This survey has the potential to pro-
vide reproducible data from a large number of participants around 
the world. In this preregistered report, we present data from 4039 
participants who reported a COVID-19 diagnosis either via Lab 
Test or Clinical Assessment and who completed the questionnaire 
during the first 11  days the study was available online. Here, we 
address 2 main research questions. First, we asked what chemosen-
sory changes are observed in participants with COVID-19 compared 
to before illness (i.e., within participants). Next, we asked whether 
the 2 diagnostic groups differ in chemosensory changes (i.e., be-
tween participants). For both diagnosis methods, we observed sig-
nificant quantitative changes in smell, taste, and chemesthesis with 
COVID-19. Most chemosensory loss could not be accounted for by 
self-reported nasal obstruction, a factor commonly associated with 
diminished smell in other upper respiratory diseases (Doty 2001). 
Further, we found little incidence of qualitative changes in olfactory 
function, with only a small percentage of participants reporting dis-
torted smells (consistent with parosmia) or phantom smells (con-
sistent with phantosmia). Together, these results provide an initial 
assessment of comprehensive chemosensory impairments associated 
with COVID-19.
Methods
Preregistration
We preregistered our hypotheses and analyses on April 19, 2020, 
at 12:20 AM Eastern Daylight Time (EDT), before the data be-
came available (data reflected questionnaires submitted between 
April 7, 2020, 6:00 AM EDT and April 18, 2020, at 8:34 AM EDT) 
(Veldhuizen et  al. 2020). In line with the preregistration, and ac-
cording to the Sequential Bayes Factor Design (section 2.3), one of 
the authors (A.J.B.) not involved in the development of the preregis-
tration queried the database to check whether the minimum number 
of participants per group was reached. The data reported in this 
manuscript, along with analysis scripts, are available at OSF (https://
osf.io/a3vkw/). The project is structured according to the research 
compendium created with the rrtools package (Marwick 2019). The 
presented analyses are as preregistered, unless specified otherwise.
The GCCR core questionnaire
The GCCR questionnaire (Supplementary Material, and included 
in the list of research tools to assess COVID-19 by the National 
Institutes of Health Office of Behavioral and Social Sciences 
Research [OBSSR; Anonymous 2020]) measures self-reported smell, 
taste, and chemesthesis function, as well as nasal blockage in parti-
cipants with respiratory illness, including COVID-19, within the 2 
weeks prior to completing the questionnaire. It was created itera-
tively through a crowd-sourced approach with a preliminary period 
of development and commentary across an international group of 
chemosensory experts, clinicians, and patients advocates. Relevant 
to the scope of the present manuscript, participants were asked to 
quantify their ability to smell, taste, and perceive cooling, tingling, 
and burning sensations (chemesthesis) before and during COVID-
19 on separate, horizontally presented, 100-point visual analogue 
scales (VAS). Participants were also asked to quantify their perceived 
nasal obstruction on a 100-point VAS with “not at all blocked” and 
“completely blocked” as anchors. Framing the questions in terms of 
ability, rather than intensity, was driven by the desire to be readily 
understood by participants without additional training or instruc-
tions and was informed by spontaneous patient reports, internet 
search trends, and in dialogue with patient advocates (e.g., we im-
plicitly separated taste/chemesthesis experienced in the mouth from 
orthonasal smell as experienced in the nose, in full alignment with 
the ecological framework first proposed by Gibson in 1966 (Gibson 
1966)). Specifically, for taste, we stated, “The following questions 
are related to your sense of taste. For example, sweetness, sourness, 
saltiness, bitterness experienced in the mouth.” For chemesthesis, we 
stated, “The following questions are related to other sensations in 
your mouth, like burning, cooling, or tingling. For example, chili 
peppers, mint gum or candy, or carbonation.” In both cases, we 
were orienting participants toward sensations that are experienced 
in the mouth. In contrast, for smell, we stated, “These questions re-
late to your sense of smell (for example, sniffing flowers or soap, or 
smelling garbage) but not the flavor of food in your mouth.” The 
within-subject nature of the present design precludes a need for 
more sophisticated scaling methods than a VAS (Kalva et al. 2014). 
That is, participants were not randomly assigned to the 2 diagnostic 
groups; however, the groups may be considered as if random when 
it comes to adjective interpretation/scale usage. This case, we argue, 
would fall within Bartoshuk’s guidelines for when valid across 
group comparisons can be made with a VAS (Bartoshuk et al. 2003). 
For a list of the questions analyzed in the present work, please see 
Supplementary Table.
Participants were also asked to report demographic information 
(i.e., year of birth, gender, and country of residence), as well as in-
formation related to their COVID-19 diagnosis and their respiratory 
illness-related symptoms, including smell and taste, in check-all-
that-apply (CATA) format. We summarized the questions used in the 
present study in Supplementary Figure S1. Please refer to the full 
questionnaire, included in the Supplementary Material, for question 
order and the labels on the anchors of each question.
The questionnaire was implemented in 10 languages as of April 
18, 2020 (the date on which the database was last queried for this 
report): English, French, German, Italian, Japanese, Kannada, 
Norwegian, Spanish, Swedish, and Turkish. Our translation protocol 
was modeled after the process developed by the Psychological Science 
Accelerator (Moshontz et  al. 2018). Briefly, translations of the ori-
ginal English questionnaire involved 3 steps: 1) the original (English) 
questionnaire was translated to the target language by independent 
translators, resulting in Translation Version A; 2) Version A was trans-
lated back from the target language to English by a separate group 
of independent translators, resulting in Version B; 3) Versions A and 
B were discussed among all translators, with the goal of resolving 
potential discrepancies between the 2 versions, resulting in the final 
Version C. All questionnaires in all languages were then implemented 
in Compusense Cloud, Academic Consortium, a secure cloud-based 
data collection platform with multilingual support. Please refer to the 
Supplementary Material for the full survey and to the questions from 
the survey analyzed in the present work (Supplementary Figure S1).
Study design
This study compares self-reported quantitative changes (during vs. 
before the illness) in smell, taste, chemesthesis, and nasal obstruc-
tion, as well as qualitative changes in smell and taste between 2 
groups of respondents: those who reported a COVID-19 diagnosis 
as a result of an objective test, such as a swab test (“Lab Test”), or 
those who reported a diagnosis from clinical observations by a med-
ical professional (“Clinical Assessment”). Given the lack of effect 
size estimates in the literature, we employed a Sequential Bayes 
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Factor Design (SBFD) that allows optional stopping with unlimited 
multiple testing (Schönbrodt et al. 2017). Specifically, we used an 
SBFD with a minimal number of participants and a temporal stop-
ping rule to increase the probability of obtaining the desired level 
of evidence and to reduce the probability of obtaining misleading 
evidence. The desired grade of relative evidence for the alternative 
versus the null (BF10) hypothesis is set at BF10 > 10 (strong evi-
dence) for H1 and BF01 > 6 (moderate evidence) for H0. We derived 
the minimal Nmin = 480 per group to start SBFD through a Bayes 
Factor Design Analysis (BFDA) for fixed-n designs (Schönbrodt and 
Wagenmakers 2018) for a 2-independent-sample, 2-sided testing, 
and a conservative Cohen’s D = 0.2 with 80% power of reaching 
a BF10 > 10 and a BF01 > 6 with a default prior. Our stopping rule 
follows a temporal criterion (data collection until April 18, 2020, 
8:34 AM EDT) and Nmin. BF computation continues with every 20 
participants added in the slowest accumulating group at a time until 
the thresholds of H1 or H0 are reached.
Study setting
Participation in this online study was voluntary and participants re-
ceived no remuneration. Inclusion criteria were: consent to partici-
pate, age 19 years and older (based on birth year), and any form or 
suspicion of respiratory illness in the past 2 weeks. Participants were 
asked about their year of birth and the onset of their illness during 
the survey to confirm the inclusion criteria, and the survey termin-
ated for noneligible participants via branching logic. The nature of 
the questionnaire necessitated at least some secondary education in 
terms of language and distribution method (web survey), as well as 
internet access. The protocol complies with the revised Declaration 
of Helsinki and was approved as an exempt study by the Office of 
Research Protections at The Pennsylvania Study University (Penn 
State) in the United States (STUDY00014904). The questionnaire 
was distributed globally in the different languages through trad-
itional (i.e., print, television, and radio) and social media (e.g., 
Twitter and Facebook), the website of the Global Consortium for 
Chemosensory Research (GCCR; https://gcchemosensr.org), flyers, 
professional networks, and word of mouth. All data were collected 
from a nonrepresentative, convenience sample via Compusense 
Cloud, which is compatible with use on a smartphone, tablet, 
laptop, or desktop computer. Data collection was compliant with 
privacy laws in the United States and the European Union (including 
California and General Data Protection regulation [GDPR] rules).
Participants
At the close of data collection on April 18, 2020, 4039 participants 
with a diagnosis of COVID-19 completed the ratings for smell, taste, 
chemesthesis ability, and nasal obstruction before and during their 
recent illness and were included in the present study. Participants 
who did not complete all ratings as mentioned above and/or gave 
inconsistent responses in 3 questions that addressed changes in smell 
perception (specifically, selecting changes in smell in “Have you had 
any of the following symptoms with your recent respiratory illness 
or diagnosis?,” reporting a difference of at least 5 points in “Rate 
your ability to smell before your recent respiratory illness or diag-
nosis” and/or selecting at least one answer for the question “Have 
you experienced any of the following changes in smell with your re-
cent respiratory illness diagnosis?”) or reported an age above 100 
(N  =  1) were excluded from the sample. Of those included in the 
final sample, 2913 were women, 1118 were men, 3 were others, and 
5 preferred not to say. Overall, the age of the participants ranged 
from 19 to 79 years old (mean ± standard deviation [SD]: 41.38 ± 
12.20 years old). 
Here, we will compare respondents from 2 diagnostic groups: 
1)  participants who reported that their COVID-19 diagnosis was 
confirmed via objective Lab Test (N  = 1402: 1064 F, 335 M; age 
mean ± SD: 40.73  ± 12.29  years old) compared with 2)  partici-
pants who reported that their COVID-19 diagnosis was obtained 
via clinical observation by a medical professional (N = 2637: 1849 
F, 783 M; age mean ± SD: 41.72  ± 12.14  years old). Based on 
self-report, respondents indicated that they resided in the following 
countries: Algeria, Argentina, Australia, Austria, Belgium, Brazil, 
Canada, Colombia, Costa Rica, Czech Republic, Denmark, Ecuador, 
Egypt, France, Germany, Greece, Iran, Ireland, Italy, Luxembourg, 
Morocco, Mexico, Netherlands, New Zealand, Norway, Paraguay, 
Portugal, Romania, Russia, Singapore, Slovenia, South Africa, Spain, 
Sweden, Switzerland, Thailand, Tunisia, Turkey, United Kingdom, 
United Arab Emirates, and United States. Figure 1 illustrates the der-
ivation of the sample presented here.
Figure 1. Flow diagram showing the selection of individual observations included in the reported analysis, as well as the observations that were excluded.
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Statistical analysis
All analyses were performed in R (Team R Core Development 2013) 
via RStudio. The scripts along with information on the computa-
tional environment and dependencies will be found, upon accept-
ance of the manuscript, at https://osf.io/a3vkw/. Information on the 
computational environment and dependencies used is also shared 
for future reproducibility. The code is also available on GitHub at 
https://github.com/GCCR/GCCR001 and includes a Jupyter note-
book replicating the core analyses in Python.
We hypothesized that there would be no difference between 
groups. Therefore, we elected for a Bayesian approach, which al-
lows us to estimate the strength of evidence supporting the null hy-
pothesis over a frequentist approach that would only allow us to 
present evidence against the null hypothesis. To test our hypotheses 
(H0: no difference between groups; H1: difference between groups) 
in this between-participant SBFD, we conducted a Bayesian linear 
regression with the lmBF function from the BayesFactor package 
(Morey and Rouder 2018) to detect changes (during minus before 
COVID-19) in smell, taste and chemesthetic abilities, as well as nasal 
obstruction. Data report the Bayes factor and no proportional error 
estimate on the Bayes factor because they were all lower than 2.07e-
05. We used the default Cauchy prior on the effect sizes under the 
H1 as the scale parameter spread, which was set at its default value 
of r  =  sqrt(2)/2. We performed robustness (sensitivity) checks by 
adjusting the Cauchy distribution to r = 0.5 and r = 1 to assess how 
the choice of prior affects the conclusions drawn from the analysis. 
We first assessed whether the model provides evidence in favor of H1 
or H0. To interpret the strength and the direction of those effects, we 
sampled from the models’ posterior distributions (iterations = 1e4). 
Please refer to the preregistration and the analysis script (see above) 
for further details. As reported in Table 1, the interpretation of the 
Bayes factors BF10 follows the classification scheme proposed by Lee 
and Wagenmakers (2013) and adjusted from (Jeffreys 1961).
Exploratory nonpreregistered analyses
To quantify the association between the reports of parosmia and 
phantosmia, smell, taste, chemesthesis, and a change in perceived 
nasal obstruction, we computed a correlation matrix that is visu-
alized with ggstatsplot (Patil and Powell 2018). To assess whether 
the proportion of parosmia and phantosmia reports differs be-
tween groups, we used a 2-sample test for equality of proportions 
with a continuity correction. To characterize the relationship be-
tween perceived nasal blockage and chemosensory change, we 
used a principal component analysis (PCA) using prcomp from 
the R default stats package and we plotted the results with func-
tions from the FactoMineR package (Lê et al. 2008). Additionally, 
to test whether different chemosensory function profiles exist in 
our sample, we performed a cluster analysis. The best clustering 
scheme was with 3 clusters as determined with NbCluster (Charrad 
et al. 2014), which tests 30 methods that vary the combinations 
of number of clusters and distance measures for the k-means clus-
tering. Cluster stability was estimated through a bootstrapping ap-
proach (100 iterations) with the bootcluster package (Yu 2017).
Results
Degree of smell loss during COVID-19
Overall, participants reported a large reduction in the sense of smell 
(−79.7 ± 28.7 points on the 100-point scale; mean ± SD; Table 2). 
Such decrease in the ability to smell was confirmed with extreme 
evidence (smell change against zero: BF10 = 4366.29 ± 0%) and that 
was similar for both groups (BF10 = 2.17 ± 0% inconclusive evidence 
for a group difference, i.e. H1; Figure 2A). The Clinical Assessment 
group exhibited a larger variance in the ability to smell during the ill-
ness as compared to the Lab Test group (Levene test, F(1,4037) = 6.81, 
P = 0.009; see also the box plots in Figure 2A).
Smell qualitative changes
Parosmia did not differ significantly between groups (X2(1) = 0.54, 
P = 0.463 [−0.01–0.03]) and was reported by 7.77% (205 out of 
2637)  of participants in the Clinical Assessment and by 7.13% 
(100 out of 1402)  in the Lab Test group. Reports of phantosmia, 
however, did significantly differ between groups (X2(1)  =  13.8, 
P  <  0.001 [0.02  –0.06]): it was reported by 9.44% (249 out of 
2637) of participants in the Clinical Assessment and by 6.28% (88 
out of 1402) in the Lab Test group. Reports of either parosmia or 
phantosmia negatively correlated with a report of a reduced ability 
to smell (on VAS) or a total smell loss (reported via CATA). Parosmia 
Table 1. Interpretation of the Bayes factors BF10 follows the 
classification scheme proposed by Lee and Wagenmakers (2013) 
and adjusted from Jeffreys (1961)
Bayes factor Evidence category
>100 Extreme evidence for H1
30–100 Very strong evidence for H1
10–30 Strong evidence for H1
3–10 Moderate evidence for H1
1–3 Anecdotal evidence for H1
1 No evidence
1/3–1 Anecdotal evidence for H0
1/10–1/3 Moderate evidence for H0
1/30–1/10 Strong evidence for H0
1/100–1/30 Very strong evidence for H0
<1/100 Extreme evidence for H0
Table 2. Mean and SD for the ratings of smell, taste, chemesthesis, and nasal obstruction before and during COVID-19 in the Clinical 
Assessment and Lab Test groups
Clinical Assessment Lab Test
 Before COVID-19 During COVID-19 Before COVID-19 During COVID-19
Variable Mean SD Mean SD Mean SD Mean SD
Smell 90.18 14.92 11.49 24.24 90.96 15.71 9.46 22.33
Taste 91.33 13.25 23.34 29.36 92.00 14.34 21.23 28.71
Chemesthesis 84.96 18.74 47.48 32.17 83.72 22.1 46.68 32.2
Nasal obstruction 9.83 18.41 31.67 32.11 9.35 17.89 32.67 31.62
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and phantosmia positively correlated with changes in smell, taste, 
and chemesthesis ratings but not with changes in perceived nasal 
obstruction (Figure 3).
Degree of taste loss in COVID-19
Similar to what was seen with smell loss, we observed an overall 
reduced ability to taste (−69.0 ± 32.6 points; mean ± SD, Table 2) 
that was confirmed with extreme evidence (taste change against 
zero: BF10 = 3424.52 ± 0%) and that was similar for both groups 
(BF10 = 0.72 ± 0% suggesting inconclusive evidence for a group dif-
ference). The Clinical Assessment group exhibited a larger variance 
in the ability to taste during COVID-19 as compared to the Lab Test 
Figure 2. Raincloud plots representing ratings for smell (A), taste (B), and 
chemesthesis (C) before (left) and during (right) COVID-19. Within each sub-
plot (from left to right), ratings from single participants are displayed as dots. 
Boxplots show the first to third quartiles, the horizontal line denotes the median, 
and whiskers denote 1.5 times the interquartile range. The density distribution of 
the data shows the proportions of given ratings. COVID-19 diagnosis is coded 
such that Clinical Assessment is a lighter shade and Lab Test is a darker shade.
Figure 3. Correlation matrices for individuals who reported parosmia (left, 
N = 296) and phantosmia (right, N = 324) across groups. The numbers refer to 
significant correlations at P < 0.001 (adjustment: Holm).
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group (Levene test: F(1,4037) = 3.91, P = 0.048; see also the box plots 
in Figure 2B).
Taste quality-specific changes 
Participants were given the option to report changes in specific taste 
qualities (i.e., salty, sour, sweet, bitter, or umami/savory) as a CATA 
question. Of all participants, 40% in both groups did not respond, 
11% in both groups reported impairment of a single taste quality, 
and 48% reported impairment of 2 or more taste qualities (48% 
in the Clinical Assessment group and 49% in the Lab Test group). 
Between groups, only umami (savory) taste change was less fre-
quently reported (25%) in the Clinical Assessment group than in 
the Lab Test group (29%; X2(1) = 7.22, P < 0.007 [−0.07 to −0.01]). 
No significant differences in the frequency of reporting changes 
for sweet, salty, bitter, or sour taste was evident between groups 
(Table 3).
Degree of chemesthesis loss in COVID-19
Similar to taste and smell, we observed an overall loss of chemesthetic 
ability (−37.3 ± 36.2; mean ± SD, Table 2) that was confirmed with ex-
treme evidence (chemesthetic change against zero: BF10 = 1459.98 ± 
0%) and that was similar for both groups (BF01 = 35.42 ± 0% sug-
gesting strong evidence against a group difference; Figure 2C). The 
distribution of chemesthetic ability showed a large 95% CI [−2.82 
to 1.88].
Perceived nasal obstruction in COVID-19
We observed a disease-related change in perceived nasal obstruction 
(22.4 plus/minus 32.4 points; mean plus/minus SD; Table 2) that was 
supported by extreme evidence (nasal obstruction change against 
zero: BF10 = 783.25 ± 0%). No difference in the change in perceived 
nasal obstruction was found between groups as corroborated by 
moderate evidence against a group difference (BF01 = 14.52 ± 0%; 
Figure 4A).
To further characterize potential relationships between changes 
in perceived nasal obstruction and reports of changes in the 3 che-
mosensory modalities, we computed a PCA (Figure  4B). Changes 
in smell, taste, and chemesthesis ratings (during minus before) cor-
related strongly with Component 1 (smell: r = 0.72; taste: r = 0.84; 
chemesthesis: r = 0.74), which explained 45.2% of the total multi-
dimensional variance (inertia). By contrast, change in perceived 
nasal obstruction was strongly anticorrelated (r = −0.97) with the 
orthogonal Component 2, which explains 24.6% of the total inertia. 
These results indicate statistical independence of changes in chemo-
sensory ability and perceived nasal obstruction. That is, changes in 
chemosensory ability and perceived nasal obstruction are statistic-
ally independent, so we conclude that changes in olfactory function 
in COVID-19 positive individuals cannot be attributed to nasal 
obstruction.
Chemosensory clustering
We used k-means algorithm to cluster respondents based on the 
similarities and differences in smell, taste, and chemesthesis change 
(Figure  5). Despite the changes being continuous in the three di-
mensions, a data-driven, 3-cluster solution (bootstrapped sta-
bility = 0.94) identified 3 groups. Based on the centroid positions, 
such groups can be described by degree of smell and taste loss and 
Table 3. Frequency of responses, by group, for changes of specific 
taste qualities during COVID-19
Taste  
change
Clinical Assessment  
(N = 2637)
Lab Test 
(N = 1402)
Sweet 1160 628
Salt 1211 629
Bitter 1036 550
Sour 980 531
Umami 668 411
Figure 4. Nasal obstruction. (A) The raincloud plot represents ratings for perceived nasal obstruction. From left to right, ratings from single participants are 
displayed as dots. Boxplots show the first to third quartiles, the horizontal line denotes the median, and whiskers denote 1.5 times the interquartile range. The 
density distribution of the data shows the proportions of given ratings. COVID-19 diagnosis is color-coded, with Clinical Assessment in lighter shade and Lab 
Test in darker shade. (B) Principal component analysis. Correlation circle of the perceptual changes with the first (abscissa) and second (ordinate) principal 
components.
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degree of chemesthesis loss. Cluster 1 (N = 1767, blue) groups par-
ticipants whose ratings are centered around substantial smell, taste, 
and chemesthesis loss (centroids: smell: −88.89, taste: −86.74, 
chemesthesis: −72.39). Cluster 2 (N = 1724, orange) groups partici-
pants whose ratings are centered around substantial smell and taste 
loss and rather unaffected chemesthesis (centroids: smell: −87.81, 
taste: −65.97, and chemesthesis: −11.07). Cluster 3 (N = 548, green) 
groups participants whose ratings are centered around moderate 
smell and taste reduction and rather unaffected chemesthesis (cen-
troids: smell: −24.33, taste: −20.97, and chemesthesis: −6.87).
Discussion
Our study confirms and substantially extends previous reports 
showing that smell loss and taste loss are associated with COVID-
19. Similar to other recent studies (Bagheri et al. 2020; Chen et al. 
2020; Gane et al. 2020; Giacomelli et al. 2020; Haldrup et al. 2020; 
Hopkins et al. 2020; Lechien, Cabaraux, et al. 2020; Lechien, Chiesa-
Estomba, et al. 2020; Mao et al. 2020; Menni et al. 2020; Moein 
et  al. 2020; Yan, Faraji, Prajapati, Boone et  al. 2020; Yan, Faraji, 
Prajapati, Ostrander 2020), we find that the majority of our parti-
cipants with COVID-19 reports a severe reduction in the ability to 
smell as compared to before the onset of that disease. Notably, this 
smell loss was not associated with self-reported nasal obstruction, 
consistent with anecdotal reports. Furthermore, we find that qualita-
tive changes in smell (smell distortions or phantoms) were relatively 
rare. We found that taste and, to a lesser degree, chemesthesis were 
also significantly impaired for individuals with COVID-19. Together, 
these results suggest that COVID-19 broadly impacts chemosensory 
function across multiple sensory modalities and that disruption of 
these may be a possible indicator of COVID-19.
This project is distinct from prior studies on the links between 
chemosensory dysfunction and COVID-19 in that it leverages a 
massive crowd-sourced, multinational approach to attack this ur-
gent issue and does so within a collaborative open science frame-
work. This initial report is based on data in 10 languages from 
41 countries; since the first tranche of data on April 18, 2020, 18 
additional languages have been added on a rolling basis. The multi-
national, collaborative nature of the GCCR approach also sets it 
apart from other recently developed tools. Our hope is that an in-
clusive globally deployed assessment, coupled with publicly access-
ible data shared under contemporary open science best practices, 
will serve as a foundation for future work. It is a limitation of this 
initial snapshot, however, that participants from different coun-
tries are not evenly represented. Cultural biases or country-specific 
manifestations of COVID-19 could potentially impact these results 
and will be explored by GCCR in future studies. Though our com-
prehensive self-report survey cannot replace in-person testing in a 
controlled clinical or laboratory setting, the gold standard for as-
sessing alterations in chemosensory function, it efficiently and effect-
ively addresses an emerging public health crisis with global scope of 
coverage. Thus, the model shown in this study of remote smell and 
taste assessment utilizing the internet may represent one way of re-
ducing delays in assessment until aggressive physical distancing ends 
(Patel 2020; Workman et al. 2020).
The mean change in ability to smell was substantial. Prior to 
the onset of COVID-19, the mean rating for the ability to smell 
was over 90 on a 100-point VAS, yet, during the disease, the mean 
rating dropped below 20. These data do not allow us to differen-
tiate between individuals with partial (hyposmia) versus total loss 
(anosmia), and participants themselves may be unable to precisely 
characterize their degree of loss in the absence of objective olfac-
tory testing (Welge-Lüssen et al. 2005; Hoffman et al. 2016; Loetsch 
and Hummel 2019). Still, we can conservatively conclude that a 
major drop in the ability to smell is a hallmark of COVID-19. If the 
prevalence of COVID-19-associated smell loss is greater than that 
reported for the common cold or influenza (Beltrán-Corbellini et al. 
2020), a different mechanism for disrupting olfactory function may 
be at play, or this difference could also reflect increased tropism of 
SARS-CoV-2 for olfactory tissues (Baig et al. 2020).
Critically, the self-reported smell loss we observed is statistically 
independent of self-reported nasal obstruction. In common URIs, 
Figure 5. (A) Correlations between the 3 principal components with respect to changes in 3 chemosensory modalities (i.e., taste, smell, and chemesthesis). 
Shades of gray indicate positive correlation, whereas shades of red indicate negative correlations. White denotes no correlation. (B) Clusters of participants 
identified by k-means clustering. The scatterplot shows each participant’s loading on dimension 1 (degree of chemesthesis loss, abscissa) and dimension 2 (de-
gree of smell and taste loss, ordinate). Loadings for participants in cluster 1 (blue, N = 1767) are characterized by significant smell and taste loss and preserved 
chemesthesis. Participants in cluster 2 (orange, N = 1724) are characterized by ratings reflecting moderate smell/taste loss and preserved chemesthesis. Loadings 
for participants in cluster 3 (green, N = 548) are characterized by significant smell, taste, and chemesthesis loss.
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nasal obstruction can explain temporary smell impairments, a phe-
nomenon many have experienced in daily life. Here, estimates of 
nasal obstruction were based solely on self-report (we asked par-
ticipants to rate the amount of “nasal blockage”); our data do not 
include objective, clinically validated measures of nasal breathing or 
obstruction. While nasal congestion does occur with COVID-19, it 
appears to be relatively rare in our sample. Still, the fact that many 
of our participants report substantial loss of olfactory function in the 
absence of concomitant nasal blockage seems remarkable.
In other instances of postviral smell loss, about half of patients 
also experience a qualitative change in smell (Frasnelli et al. 2004; 
Reden et al. 2007; Rombaux et al. 2009). By contrast, less than 10% 
of participants in this study reported parosmia or phantosmia symp-
toms. The rarity of qualitative changes in smell may be a hallmark of 
COVID-19 associated smell impairments. Alternatively, the present 
study may not have fully captured qualitative changes in smell, as 
they tend to emerge later in the course of other disorders (Bonfils 
et al. 2005) and the present assessment was limited to within at most 
2 weeks of suspected illness or diagnosis. Further studies are needed 
to more comprehensively address this issue. 
Although taste loss has also been associated with COVID-19 in 
patient anecdotes and a few studies, in most cases it has not been 
clearly differentiated from changes in smell. Here, we found that 
ratings of taste function were, like those for smell, substantially de-
creased in individuals with COVID-19. Participant ratings for taste 
function dropped from a mean of ~91 before COVID-19 onset to less 
than ~24 during the disease. It is well established that people often 
confuse changes in retronasal olfaction—an important component 
of flavor perception during eating and drinking—with a true taste 
loss. Although we cannot completely rule this out given the study de-
sign, ~60% of those reporting a taste loss also reported a decrease in 
their perception of at least one specific taste quality, with salty taste 
being the most common selection. The question on taste qualities 
is a CATA question, which means that the subjects can choose any 
taste qualities that they believe were clearly affected. Indeed, many 
of the participants chose multiple taste qualities. These data sup-
port an interpretation that at least some participants were properly 
discerning taste from flavor. The observation that some participants 
reported loss of only a subset of taste qualities may reflect their dif-
ficulty in correctly identifying and naming individual taste qualities 
(Pilkova et al. 1991; Welge-Luessen et al. 2011) rather than quality-
selective hypogeusia/ageusia (e.g., Henkin et al. 1970; Lugaz et al. 
2002; Gudziol and Hummel 2007; Huque et  al. 2009). However, 
these possibilities cannot be clarified with the present database. 
Compared to smell, the literature has described fewer examples 
of postviral taste loss (Adour 1994; Rubin and Daube 1999). As 
the number of people responding to this questionnaire continues to 
grow on a rolling basis, the differences among different types of re-
spiratory illnesses and their relationship to the degree of taste loss 
will be a major focus of forthcoming analyses. 
Perhaps our most surprising finding was a notable loss of oral 
chemesthesis ability with COVID-19. Though the decrease is not 
as large as seen for smell and taste—an ~46% rating reduction for 
chemesthesis as compared to ~89% and ~76% percentage drop in 
smell and taste, respectively—it is significant. Interestingly, impair-
ment of chemesthesis was typically accompanied by either taste and 
smell loss, whereas taste and smell loss could appear with normal 
chemesthesis. Whereas nasal chemesthesis experienced with the in-
halation of noxious chemicals like ammonia or ethanol is sometimes 
confused with smell, oral chemesthesis responses to compounds like 
capsaicin from chili peppers or menthol from mint rarely is (Green 
1996). Though predominantly thought of as the chemical activa-
tion of trigeminal afferents carrying temperature, pain, or vibration 
information from the oral, nasal, and eye mucosa, other somato-
sensory nerves, including in the mouth, can also be affected (Green 
1996; McDonald et  al. 2016). Chemesthesis (and taste) has been 
reported to accompany postviral hyposmia resulting from a URI, 
at least in some cases (Ren et al. 2012; Fark and Hummel 2013; de 
Haro-Licer et  al. 2013; Pellegrino et  al. 2017). Together with our 
findings for smell and taste, these data suggest that SARS-CoV-2 
impacts all 3 major chemosensory modalities. The mechanisms are 
not clear and may be distinct for each chemosensory system. For 
example, transcriptomic studies of the olfactory mucosa of mouse 
and human suggests that sustentacular, Bowman’s gland, microvil-
lous cells, and stem cell populations, not olfactory sensory neurons 
themselves, contain ACE2, a receptor required for SARS-CoV-2 viral 
entry into cells (Brann et al. 2020; Fodoulian et al. 2020). The pattern 
of ACE2 expression indicates that SARS-CoV-2 may infect tongue 
keratinocytes (Venkatakrishnan et al. 2020), but it is not known if 
taste receptor cells or cranial nerves carrying taste or chemesthetic 
information can be infected by SARS-CoV-2. This virus could alter-
natively infect surrounding epithelia or blood vessels (Sungnak et al. 
2020; Varga et al. 2020) or, perhaps, even target cells of the central 
nervous system (Baig et al. 2020).
Based on the stark changes in ratings reported here, one may 
speculate that both smell and taste loss in COVID-19 are all-or-none 
phenomena. Although, we cannot rule out that this is an artifact of 
scale usage, this explanation seems unlikely, as the distribution of the 
chemesthetic ability ratings is roughly rectangular. This suggests that the 
all-or-none effect observed for smell cannot be simply attributed to par-
ticipants using the scale in a discrete rather than continuous fashion. The 
self-reporting of olfactory function has been used in numerous studies; 
however, it is not unanimously accepted as it may suffer from low 
validity (Landis et al. 2003) due to underreporting and overreporting 
biases (Dalton and Hummel 2000; Oleszkiewicz et al. 2020) and pos-
sible arbitrary usage. These studies all indicate that self-report ratings 
are far from being completely inaccurate, especially in participants with 
severe hyposmia or anosmia, with reported accuracy rates of 70–80% 
(Rawal et al. 2015; Hoffman et al. 2016; Lötsch et al. 2019).
Here, we account for well-known individual differences in baseline 
chemosensory abilities, as well as the use of rating scales, by using a 
within-subject design where participants rate their abilities for different 
time points (before and during COVID-19). We perform an analysis of 
differences between 2 assessments (e.g., during minus before COVID-
19) rather than on absolute ratings. To better address the question of 
validity of change in ability ratings, future studies should compare these 
self-reported and recalled ratings to validated clinical tests before and 
during the individual’s respiratory illness. However, in times of pan-
demic, the advantages of a remote assessment method may outweigh 
the potential decrease in validity compared to face-to-face clinical meas-
ures of taste and smell. Still, we acknowledge that a convenience sample 
recruited online may not be representative of the general population; 
thus, our study and others that use this type of recruitment approach 
(e.g., Iravani et al. 2020; Menni et al. 2020) should not be used to esti-
mate prevalence of chemosensory loss in individuals with COVID-19.
Lastly, we found that mean impairments of smell, taste, and 
chemesthesis did not differ between study participants who reported 
a COVID-19 diagnosis based on a Lab Test and those who reported 
diagnosis based on a Clinical Assessment. However, the Clinical 
Assessment group exhibited a larger variance in chemosensory loss 
than the Lab Test group. This could reflect more variability in the ac-
curacy of the diagnosis as the Clinical Assessment group may include 
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individuals who were misdiagnosed and actually have another viral 
illness and/or a milder form of the disease. Determining whether the 
degree of change in chemosensory ability differs between COVID-
19-positive individuals and those who are COVID-19-negative but 
have another respiratory disease will require specific comparisons 
between those 2 groups in a future study.
Conclusions
The GCCR consortium shows how health professionals, clinicians, 
patient advocates, and scientists can work together to undertake 
large-scale ground-breaking research of acute public health signifi-
cance. The present research sets an example of how an emergent 
response to a global pandemic can be tackled with a crowd-sourced 
initiative that combines rigorous scientific standards with open-
science practices. The established network, research infrastructure, 
protocol, and findings have the potential to influence current the-
ories on the effects and mechanisms of COVID-19 on the chemical 
senses and to fuel future research in other areas.
Supplementary material
Supplementary material can be found at Chemical Senses online.
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